INBSHealthcare · Medical Devices

INBS Stock Forecast: Intelligent Bio Solutions, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$2.13

−2.74% on the day

The 1 Wall Street analysts covering Intelligent Bio Solutions, Inc. hold a median 12-month price target of $12 — +463.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 11 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$6.4M

Ticker Nerd rank

11 / 100

Median analyst target

$12

Analysts covering

Revenue$1.1M+35.8% y/y

Operating income−$4.0M

Net income−$3.9M

Free cash flow−$3.2M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−7.4%

+3.9%

YTD

−77.6%

−87.7%

From 52W high

−88.7%

From 52W low

+37.4%

$19

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

INBS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Intelligent Bio Solutions, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026

11 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Growth

Revisions

Accruals

Value

Momentum

Quality

Volatility

Issuance

Size (95): Smaller than most of the companies we track.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INBS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INBS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $12Median $12High $12

The green dot is the last close — the median target sits +463.4% from it.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INBS appears on the weeks it earns a place.

Performance

INBS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Intelligent Bio Solutions, Inc. returned −87.7% against +17.5% for the S&P 500, dividends included.

INBS vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INBS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Intelligent Bio Solutions, Inc. (INBS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 10.1×
Price / sales: 1.5×
Price / book: 1.1×
EV / EBITDA: −0.3×

Growth & margins

Revenue growth (YoY): 35.8%
Earnings growth (YoY): 35.8%
Gross margin: 46.8%
Operating margin: −346.0%
Net margin: −294.9%

Returns & dividend

Return on equity: −307.7%
Return on assets: −76.2%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Intelligent Bio Solutions, Inc. (INBS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Intelligent Bio Solutions, Inc. has a market value of $6.4M and an enterprise value of $3.9M.
Revenue in the twelve months to 30 June 2026: $4.2M. The latest quarter grew 35.8% year on year.
Net income over the same four quarters: −$12.5M, a −295.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$12.1M.
Shares outstanding: 2.9M.
Trailing P/E: 10.1×; forward P/E: 6.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Intelligent Bio Solutions, Inc. employs 59 people — $71K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

INBS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
INBSIntelligent Bio Solutions, Inc.	$6.4M	11
TNONTENON Medical, Inc.	$6.1M	56
AIDX20/20 Biolabs, Inc.	$6.9M	3
VNRXVolitionRX Ltd.	$5.8M	38
NVNOenVVeno Medical Corp.	$7.3M	32
ICCMIceCure Medical Ltd.	$7.6M	38
CODXCo-Diagnostics, Inc.	$7.8M	37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Intelligent Bio Solutions, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INBS news & analysis

Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET

GlobeNewsWire · 10 Sept 2026neutral

Intelligent Bio Solutions announced it will host a virtual fireside chat on September 24th at 4:30 p.m. ET. Management is scheduled to discuss its FDA 510(k) submission, clinical data, and commercial progress outside the United States.

Why it matters — INBS watchers would care because the session is expected to provide updates on the company's regulatory and clinical milestones and its international commercial activities.

Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance

GlobeNewsWire · 9 Sept 2026neutral

Intelligent Bio Solutions announced it submitted a 510(k) premarket notification to the U.S. FDA, seeking regulatory clearance of its Intelligent Fingerprinting Drug Screening System for the detection of the opiate codeine. The submission is a step toward potential U.S. market availability for the system.

Why it matters — INBS watchers would care because this FDA submission represents progress toward potential U.S. market clearance for the company's non-invasive drug screening technology.

Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission

GlobeNewsWire · 1 Sept 2026positive

Intelligent Bio Solutions announced that a multi-site clinical method comparison study of its Intelligent Fingerprinting Drug Screening System achieved above 98% accuracy. The strong performance data supports the company's planned 2026 FDA 510(k) submission for the system.

Why it matters — This positive validation of the drug screening system's accuracy is a key step toward the regulatory submission that could expand INBS's market prospects.

Intelligent Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under Nasdaq Rules

GlobeNewsWire · 1 Sept 2026neutral

Intelligent Bio Solutions announced a private placement of up to $15 million with a single existing institutional investor, priced at-the-market under Nasdaq rules. The placement includes $5 million upfront at closing and a $5 million tranche warrant callable by the company following FDA 510(k) clearance of its Intelligent Fingerprinting Drug Screening System.

Why it matters — The company secured potential financing that is tied to the regulatory clearance of its fingerprint-based drug screening system, which will be of interest to INBS watchers following the product's FDA progress.

Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth

GlobeNewsWire · 19 Aug 2026positive

Intelligent Bio Solutions, Inc. reported fiscal 2026 full-year revenue growth of 38% year-over-year, driven by a 22% growth in its reader installed base and a 35% increase in total consumable cartridges to over 100,000 units, which the company attributes to high-margin cartridge growth.

Why it matters — The 38% annual revenue growth, driven by an expanding installed base and rising high-margin cartridge sales, indicates strengthening recurring revenue from Intelligent Bio Solutions' core diagnostic reader business.

FAQ

Frequently asked questions about INBS stock

What is the INBS stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Intelligent Bio Solutions, Inc. have a median 12-month price target of $12, with estimates ranging from $12 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INBS stock a buy right now?

Of the 1 analysts covering Intelligent Bio Solutions, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Intelligent Bio Solutions, Inc. 11 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INBS?

As at 12 Sept 2026, Intelligent Bio Solutions, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

Will INBS stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +463.4% from the last close, and Ticker Nerd's factor model ranks Intelligent Bio Solutions, Inc. 11 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INBS stock forecast for 2030?

No analyst covering Intelligent Bio Solutions, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INBS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.

How has INBS stock performed over the past year?

Intelligent Bio Solutions, Inc. returned -87.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Intelligent Bio Solutions, Inc. do?

Intelligent Bio Solutions Inc. is a medical technology company focused on delivering rapid, non-invasive testing and screening solutions.

What is the latest news on INBS?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET". Intelligent Bio Solutions announced it will host a virtual fireside chat on September 24th at 4:30 p.m. ET. Management is scheduled to discuss its FDA 510(k) submission, clinical data, and commercial progress outside the United States.

Company

About Intelligent Bio Solutions, Inc.

Intelligent Bio Solutions Inc. is a medical technology company focused on delivering rapid, non-invasive testing and screening solutions. The company’s current offerings center on the Intelligent Fingerprinting platform, which uses fingerprint sweat analysis with a portable handheld reader and single-use cartridge to support drug screening in workplace and other safety-critical settings. It also develops a biosensor platform aimed at diagnostic and monitoring applications, including clinical chemistry, immunology, hormones, tumor markers, and nucleic acid testing. Intelligent Bio Solutions serves customers across the United States, the United Kingdom, Asia Pacific, and other international markets, positioning itself in the broader medical diagnostics and life sciences sector. Headquartered in New York, the company concentrates on tools that combine portability, speed, and non-invasive sample collection for practical use in professional testing environments.

CEO Mr. Harry Simeonidis · 59 employees · United States · https://ibs.inc